The impact of perennial malaria chemoprevention on key health outcomes in children aged 2–18 months: Results from a cluster-randomised controlled trial in Nigeria

Published:

Resources: Presentation

Authors: Olusola Oresanya

Perennial malaria chemoprevention is associated with reductions in all-cause consultations, cases of clinical malaria and cases of severe malaria; improved coverage is expected to lead to greater impact.

The Perennial Malaria Chemoprevention (PMC) Effect Study is a type 2 hybrid effectiveness-implementation study delivering sulfadoxine-pyrimethamine (SP) in the first and second years of life in Nigeria. It aims to catalyse decision-making in Nigeria regarding policy adoption of PMC.

This presentation was given at the 2025 Annual Meeting of the American Society of Tropical Medicine and Hygiene, held on 9-13 November in Toronto, Canada.

Share this page

Tagged under:

TH C Pr ASTMH 2025 Sola

Conference
American Society of Tropical Medicine and Hygiene Annual Meeting

THIS IS A DEMO